Tiazotic acid

Tiazotic acid
Clinical data
Trade names	Thiotriazoline; Tiokor
Identifiers
	IUPAC name 2-[(5-Methyl-1H-1,2,4-triazol-3-yl)sulfanyl]acetic acid;
CAS Number	64679-65-8 ; 357172-63-5 (morpholine salt);
PubChem CID	254566;
UNII	YEZ00M9XKN;
KEGG	D10852;
ChEMBL	ChEMBL1487672;
CompTox Dashboard (EPA)	DTXSID40214967 ;
ECHA InfoCard	100.244.688
Chemical and physical data
Formula	C5H7N3O2S
Molar mass	173.19 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC(=NN1)SCC(=O)O;
	InChI InChI=InChI=1S/C5H7N3O2S/c1-3-6-5(8-7-3)11-2-4(9)10/h2H2,1H3,(H,9,10)(H,6,7,8); Key:OJUNWHNRDPRNBR-UHFFFAOYSA-N;

Tiazotic acid (brand names Thiotriazoline and Tiokor) is an antioxidant. It is used as a pharmaceutical drug for the treatment of ischemic heart disease in Russia, Ukraine, and Uzbekistan.^[1]^[2]

It is used as its salt with morpholine.^[3]

It has been studied for its potential to improve the cardiac effects of COVID-19.^[4]

References

^ "Tiazotic acid". Inxsight Drugs. National Center for Advancing Translational Sciences.
^ Kadin DV, Chumak BA, Filippov AE, Shustov SB (2015). "[Thiotriazoline in the Treatment of Stable Angina Pectoris of II-III Functional Class]". Kardiologiia. 55 (8): 26–29. doi:10.18565/cardio.2015.8.26-29. PMID 26761968.
^ Shishkina SV, Baumer VN, Khromileva OV, Kucherenko LI, Mazur IA (2017). "The formation of two thiotriazoline polymorphs: Study from the energetic viewpoint". CrystEngComm. 19 (17): 2394–2401. doi:10.1039/C7CE00117G.
^ Belenichev I, Kucherenko L, Pavlov S, Bukhtiyarova N, Popazova O, Derevianko N, et al. (2022). "Therapy of post-COVID-19 syndrome: Improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (Thiotriazoline)". Pharmacia. 69 (2): 509–516. doi:10.3897/pharmacia.69.e82596.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[1] "Tiazotic acid". Inxsight Drugs. National Center for Advancing Translational Sciences.

[2] Kadin DV, Chumak BA, Filippov AE, Shustov SB (2015). "[Thiotriazoline in the Treatment of Stable Angina Pectoris of II-III Functional Class]". Kardiologiia. 55 (8): 26–29. doi:10.18565/cardio.2015.8.26-29. PMID 26761968.

[3] Shishkina SV, Baumer VN, Khromileva OV, Kucherenko LI, Mazur IA (2017). "The formation of two thiotriazoline polymorphs: Study from the energetic viewpoint". CrystEngComm. 19 (17): 2394–2401. doi:10.1039/C7CE00117G.

[4] Belenichev I, Kucherenko L, Pavlov S, Bukhtiyarova N, Popazova O, Derevianko N, et al. (2022). "Therapy of post-COVID-19 syndrome: Improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (Thiotriazoline)". Pharmacia. 69 (2): 509–516. doi:10.3897/pharmacia.69.e82596.

[1]

[2]

[3]

[4]